Anthony Petrone’s rating is based on several promising developments regarding LivaNova’s OSPREY study for treating obstructive sleep apnea (OSA). The company announced favorable 6-month results from ...

Needham analyst Michael Matson has maintained their bullish stance on LIVN stock, giving a Buy rating on October 31. Michael Matson has given ...

LivaNova met the primary endpoints for its OSPREY trial, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation.

LivaNova today announced that its OSPREY trial of nerve stimulation for treating sleep apnea met its primary endpoints.

1 of 1' marketing platform, and our commitment to our... LivaNova PLC , a market-leading medical technology company, today announced that it met the primary endpoints for its OSPREY randomized ...

Mizuho analyst Anthony Petrone lowered the firm’s price target on LivaNova (LIVN) to $70 from $80 and keeps an Outperform rating on the shares following the Q3 report. The firm still sees $4 in ...

LivaNova PLC (NASDAQ:LIVN), is not the largest company out there, but it saw a double-digit share price rise of over 10% in the past couple of months on the NASDAQGS. Shareholders may appreciate ...

Welcome to LivaNova's conference call for the third ... In OSA, we are encouraged by the early stoppage in enrollment of the OSPREY study in March, which was based on a determination that there ...

LivaNova (LIVN) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.73 per share a year ago. These figures ...

LONDON (AP) — LONDON (AP) — LivaNova PLC (LIVN) on Wednesday reported third-quarter net income of $33 million. The London-based company said it had net income of 60 cents per share.